Immune checkpoints as therapeutic targets in autoimmunity

Antibodies that block the immune checkpoint receptors PD1 and CTLA4 have revolutionized the treatment of melanoma and several other cancers, but in the process, a new class of drug side effect has emerged-immune related adverse events. The observation that therapeutic blockade of these inhibitory re...

詳細記述

書誌詳細
主要な著者: Paluch, C, Santos, A, Anzilotti, C, Cornall, R, Davis, S
フォーマット: Journal article
言語:English
出版事項: Frontiers Media 2018

類似資料